THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 9, 2005--Amgen
(NASDAQ:AMGN), the world´s largest biotechnology company, today
announced that it filed a lawsuit in the United States District Court
in Boston, Massachusetts against F. Hoffmann-LaRoche Ltd., Roche
Diagnostics GmbH, and Hoffmann-LaRoche, Inc., seeking a declaration by
the Court that defendants´ importation, use, sale or offer to sell a
pegylated version of recombinant human erythropoietin infringe Amgen´s
patents. Amgen alleges infringement of six U.S. patents owned by Amgen
that claim erythropoietin (EPO) products and pharmaceutical
compositions, and processes for making EPO. Amgen seeks a permanent
injunction preventing the defendants from making, importing, using,
offering for sale or selling recombinant human EPO, including
pegylated EPO, in the United States.
Amgen markets a recombinant human EPO product in the United States
as EPOGEN(R) (Epoetin alfa) for the treatment of anemia associated
with chronic renal failure for patients on dialysis. Amgen´s patent
rights on erythropoietin protect Amgen´s breakthrough inventions.
About EPOGEN(R) (Epoetin alfa)
EPOGEN (Epoetin alfa) is indicated for the treatment of anemia in
patients with chronic renal failure on dialysis. EPOGEN is
contraindicated in patients with uncontrolled hypertension. For
additional product information, please see www.Epogen.com.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
EDITOR´S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Mary Klem, 805-447-4587 (media)
Arvind Sood, 805-447-1060 (investors)